Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series
Xiuning Le,Anna Eisert,Te-Chun Hsia,Nirmal Vivek Raut,Azura Ahmad,Oscar Siu Hong Chan, Charlotte De Bondt,David Farrugia,Patrizia Froesch,Maria Gonzalez-Cao,Lizza Hendriks,Maximilian J. Hochmair,Julien Mazieres,Hazel O'Sullivan,Jens Samol, Anthonie J. van der Wekken,Tsung-Ying Yang,Kirti Joshi,Soetkin Vlassak,Gee-Chen Chang JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
